Moderna’s Flu/COVID-19 Vaccine Shows Promise Amidst US Regulatory Challenges
Moderna is navigating regulatory hurdles in the United States even as simultaneously demonstrating promising results with its experimental combination vaccine targeting both influenza and COVID-19. Recent research too sheds light on potential links between gut bacteria and non-celiac gluten sensitivity.
Moderna’s mRNA Flu and COVID Vaccine: Mid-Phase Trial Results
A two-in-one mRNA vaccine developed by Moderna is showing encouraging results in a mid-phase trial. The vaccine aims to provide simultaneous protection against seasonal influenza and COVID-19 by delivering mRNA instructions that enable the body to produce proteins from flu strains and the original COVID-19 virus, effectively training the immune system to recognize and combat both threats.
The study, involving 550 healthy U.S. Adults aged 18 to 75, compared the investigational combination vaccine to a placebo and to separate injections of Moderna’s commercially available mRNA flu and COVID vaccines. Published in the journal Human Vaccines and Therapeutics, the results indicate that “a single dose of mRNA-1073 elicited durable immune responses for six months against all vaccine-matched influenza and SARS-CoV-2 strains.”
Researchers concluded that these findings support further evaluation of multi-component mRNA vaccines as a potential single-dose solution for simultaneous protection against influenza and COVID-19.
Shifting Focus Outside the US
Moderna is actively exploring opportunities to expand its revenue streams outside of the United States. This strategic shift comes after the Department of Health and Human Services, under the leadership of Robert F. Kennedy Jr., canceled a $600 million government contract for the development of mRNA vaccines against avian flu and other high-risk strains [1]. This decision reflects a growing skepticism towards mRNA technology within the current US administration.
Non-Celiac Gluten Sensitivity: A Gut Microbiome Connection
Emerging research suggests a potential link between disruptions in the gut microbiome and non-celiac gluten sensitivity. Up to 15% of the population experiences digestive symptoms after consuming gluten without exhibiting the intestinal damage characteristic of celiac disease [3].
A study conducted on mice revealed that antibiotic treatment, which alters the composition of gut bacteria, led to changes in how gluten was processed and increased the immune response to gluten. Researchers found greater inflammation and an increased immune response to gluten after antibiotic treatment. This suggests that the microbiome may play a crucial role in determining the body’s reaction to gluten and could provide insights into the underlying mechanisms of non-celiac gluten sensitivity [3].
“This perform suggests that the microbiome may determine the ability of gluten to induce an immune response and provides valuable insight into the mechanism underlying non-celiac gluten sensitivity,” the researchers wrote.